Cantargia plans Phase 1b/2a trial of nadunolimab plus RAS inhibitor in pancreatic cancer

Bitget2026/09/30 05:03

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Cantargia flagged new preclinical evidence backing nadunolimab combined with RAS inhibition in pancreatic ductal adenocarcinoma.
Results were presented in a poster at the AACR Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development.
Study showed the combination reshaped the tumor microenvironment, reduced immune suppression, reduced tumor burden versus either approach alone.
Data support a planned Phase 1b/2a trial testing nadunolimab with a RAS inhibitor in pancreatic cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cantargia AB published the original content used to generate this news brief on September 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Cantargia plans Phase 1b/2a trial of nadunolimab plus RAS inhibitor in pancreatic cancer

You may also like

Crypto prices